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ABSTRACT
Objective To describe the clinical features and
effectiveness of oseltamivir on disease progression and
viral RNA shedding in patients with mild pandemic 2009
influenza A(H1N1) virus infection.
Design Opportunistic retrospective review of medical
charts of patients with confirmed 2009 H1N1 identified
through the national surveillance system in China from
May to July 2009.
SettingUndercoordinationoftheMinistryofHealth,local
healthdepartmentswereaskedtocollectmedicalrecords
of confirmed patients and send them to the Chinese
Centre for Disease Control and Prevention on a voluntary
basis as part of the public health response.
Population 1291 patients with confirmed 2009 H1N1
infection and available data for chart review.
Main outcome measures Demographic characteristics,
comorbidities, symptoms and signs, laboratory tests,
findings on chest radiography, antiviral treatment,
duration of fever, and duration of viral RNA shedding.
Results The median age of 1291 patients was 20 years
(interquartile range 12-26); 701 (54%) were male. The
most common symptoms were fever (820, 64%), cough
(864, 67%), sore throat (425, 33%), sputum (239, 19%),
and rhinorrhoea (228, 18%). Of 920 patients who
underwent chest radiography, 110 (12%) had abnormal
findings consistent with pneumonia. Some 983 (76%)
patients were treated with oseltamivir from a median of
the third day of symptoms (2-4). No patients required
admission to the intensive care unit or mechanical
ventilation. 2009 H1N1 was shed from one day before
onset of symptoms to up to eightdays after onset in most
(91%)patients,withamedianof5(3-6)daysofshedding
after onset. Treatment with oseltamivir significantly
protected against subsequent development of
radiographically confirmed pneumonia (odds ratio 0.12,
95% confidence interval 0.08 to 0.18), and treatment
started within two days of symptom onset reduced the
duration of fever and viral RNA shedding.
Conclusions Chinese patients with 2009 H1N1 infection
predominantlypresentedwithfeaturesofuncomplicated,
self limiting acute respiratory illness. 2009 H1N1 might
be shed longer than seasonal influenza virus. Treatment
with oseltamivir was associated with a significantly
reduced development of radiographically confirmed
pneumonia and a shorter duration of fever and viral RNA
shedding. Though these patients benefited from
treatment,thefindingsshouldbeinterpretedwithcaution
as the study was retrospective and not all patients
underwent chest radiography.
INTRODUCTION
Pandemic 2009 influenza A(H1N1) virus has spread
rapidly, resulting in millions of laboratory confirmed
casesandover18000deathsinover200 countries.
1In
June 2009 the global spread prompted the World
Health Organization to declare the first influenza pan-
demic of the 21st century. Since then, the clinical
understanding of 2009 H1N1 infections has increased
but has mostly focused on severely ill patients and
those admitted to hospital,
2-10 except for one report
from China.
11 The spectrum of the disease ranges
from asymptomatic to non-febrile and from mild
upper respiratory tract illness to severe or fatal pneu-
monia, and there is controversy about the different
impact of antiviral treatment in these groups of
patients.
12 Randomised controlled trials conducted
on “old” seasonal influenza (1970 to 2008-9) showed
thattreatmentwithneuraminidaseinhibitorswithin48
hoursofonsetofsymptomscanreducetheseverityand
duration of symptoms and possibly the risk of
complications.
13-17 The extent to which treatment
withneuraminidaseinhibitorsmightbenefit otherwise
healthy individuals with mild 2009 H1N1 infection,
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experience a new period of seasonal influenza with
2009 H1N1, the dominant virus worldwide.
18
China established enhanced national surveillance
for patients with 2009 H1N1 on 30 April 2009, and a
containment policy was implemented immediately,
which included isolation of all confirmed patients,
early treatment with oseltamivir, and a set of strict dis-
charge criteria, regardless of clinical severity. On 11
May 2009, the first case of 2009 H1N1 infection was
identified in China.
We carried out an opportunistic retrospective
review of medical charts to describe the clinical fea-
tures and effectiveness of oseltamivir on progression
of disease and viral RNA shedding in patients with
mild 2009 H1N1 infection among 1291 laboratory
confirmed cases identified through the national sur-
veillance from May to 31 July 2009.
METHODS
National surveillance for pandemic H1N1
All suspected cases of 2009 H1N1 were identified
through active surveillance with screening at borders
and medical monitoring of close contacts of patients
with confirmed disease or through passive reporting
by clinicians when those patients sought medical con-
sultations. All suspected and laboratory confirmed
cases were reported to the Chinese Centre for Disease
Control and Prevention.
A case of acute respiratory illness was defined as a
patient with fever (axillary temperature ≥37.3°C) or
recent onset of at least one of rhinorrhoea, nasal con-
gestion, sore throat, or cough. A suspected case was
defined as a person with acute respiratory illness and
onset of illness within seven days of travel to an area
withconfirmedcasesorwithinsevendaysofclosecon-
tact with a confirmed case. A confirmed case was
defined as a patient with acute respiratory illness and
laboratory evidence of 2009 H1N1 infection diag-
nosed by real time reverse transcription polymerase
chain reaction testing of respiratory specimens.
Patients
During the early stage of the pandemic (until to 31
July), all patients with suspected 2009 H1N1, regard-
less of clinical severity, were admitted to designated
hospitals and treated with a standard dose of
oseltamivir.
1920 Upper respiratory specimens (nasal,
throat, and nasopharyngeal swabs) were collected
and placed in sterile viral transport medium for 2009
H1N1 testing. RNA was extracted from specimens
with the RNeasy Mini Kit (Qiagen, Valencia, CA,
USA) and tested by real time reverse transcription
polymerase chain reaction following the protocol of
the US Centres for Disease Control and Prevention.
21
Assays were performed in the National Influenza Sur-
veillanceNetworkof63laboratoriesandconfirmedby
the National Influenza Centre. During the early phase
of the 2009 H1N1 outbreak the infectious period was
unknown, and the Ministry of Health of China recom-
mendedthetakingofadditionalrespiratoryspecimens
to determine viral clearance dynamics with molecular
analysis.
22 The criteria for discharge from hospital
were normal body temperature recorded on two con-
secutivedays,resolutionofrespiratorysymptoms,and
two respiratory specimens with negative results col-
lected over two consecutive days.
22
Table 1 |Demographic characteristic and comorbidities of 1291 patients with 2009 H1N1
virus infection in China, May-July 2009. Figures are numbers (percentages) unless stated
otherwise
Characteristic
All patients
(n=1291)
Children <15 years
(n=406)
Adults ≥15 years
(n=885)
Male 701 (54) 215 (53) 486 (55)
Median (IQR) age (years) 20 (12-26) 9 (7-11) 23 (19-33)
Age group (years):
0-4 35 (3) 35 (9) —
5-14 371 (29) 371 (91) —
15-24 511 (40) — 511 (58)
25-49 315 (24) — 315 (36)
50-64 52 (4) — 52 (6)
≥65 7 (0.5) — 7( 0 . 8 )
Comorbidity associated with severe influenza*:
Any 64 (5) 14 (3) 50 (6)
Asthma 29 (2) 13 (3) 16 (2)
Other chronic pulmonary disease† 10 (0.8) 1 (0.2) 9 (1)
Chronic liver disease 10 (0.8)‡ 0 (0) 10 (1)‡
Type 1 or 2 diabetes 9 (0.7) 1 (0.2) 8 (0.9)
Coronary artery disease 4 (0.3) 0 (0) 4 (0.5)
Pregnancy 2 (0.2)§ 0( 0 ) 2( 0 . 2 ) §
Chronic renal disease 1 (0.1) 0 (0) 1 (0.1)
Immunosuppression 1 (0.1)¶ 0( 0 ) 1( 0 . 1 ) ¶
Neurological disease 0 (0) 0 (0) 0 (0)
Current smoker 74/1176 (6) 1/357 (0.3) 73/819 (9)
Influenza vaccination, 2008-9 season 30/515 (6) 15/166 (9) 15/349 (4)
IQR=interquartile range.
*Comorbidities not mutually exclusive; some patients had multiple chronic comorbid diseases. Data unavailable
for three children and three adults.
†Includes chronic bronchitis (5), emphysema (2), bronchiectasis (2), chronic bronchitis and bronchiectasis (1).
‡Includes hepatitis B and fatty liver.
§Both in second trimester (at 13 weeks’ gestation).
¶After heart transplantation.
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Fig 1 | Onset and disappearance of fever over clinical course by
days after onset of symptoms in 1219 febrile patients with
2009 influenza H1N1 virus infection
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We retrospectively reviewed medical charts to collect
data on patients with confirmed infection identified
through the national surveillance system from May to
31 July 2009. Beginning in August, as 2009 H1N1
activity expanded, the national policy changed to
focus on identifying patients admitted to hospital and
continuing routine sentinel influenza surveillance.
Only patients who required hospital care were
admitted, while patients with milder infection were
cared for at home. Under coordination of the Ministry
of Health, local health departments were asked to col-
lect medical records of patients with confirmed infec-
tion and send them to the Chinese Centre for Disease
Control and Prevention on a voluntary basis as part of
the public health response. In this study we included
patients with available data who were discharged dur-
ing the study period that ended on 31 July.
Medical epidemiologists reviewed medical charts
and extracted data using a standardised form that
included demographics, comorbidities, symptoms
and signs, laboratory tests, findings on chest radio-
graphy, complications, treatment, course, and out-
come and results of reverse transcription polymerase
chain reaction. The first negative result of two conse-
cutive respiratory specimens was considered to indi-
cate an undetectable viral RNA level. We could not
determinetheactualonsetoffeverorthepreadmission
dynamicsofviralRNAsheddingandtherefore,unlike
in another recent report,
11 during hospital admission
we defined duration of fever as the number of days
between onset of symptoms and return to normal
body temperature; duration of viral RNA shedding
was defined as the number of days between onset of
symptoms and undetectable viral RNA level.
Statistical analysis
Data were doubleentered ona computerised database
using Microsoft Access. Descriptive statistics included
frequencyanalysisforcategoricalvariables,meansand
standard deviations for normal distributions, or med-
ians and interquartile ranges for continuous variables.
We used two sample t tests, Wilcoxon rank sum test,
andKruskal-WallisHtestforcontinuousvariablesand
χ
2 test or Fisher’s exact test for discrete variables in
bivariate analyses.
We used multivariable logistic regression models to
identifyriskfactorsassociatedwithsubsequentdevelop-
ment of radiographic pneumonia and calculated odds
ratios and 95% confidence intervals. Numbers needed
to treat equal to 1/absolute risk reduction were esti-
mated. Based both on relations within the cohort and
data from other publications, we considered age, sex,
comorbidities, smoking, influenza vaccination, and
treatment with oseltamivir and antibiotics as candidate
variables.Weexcludedfromthemodelsthevariableof
days between onset of illness and admission to hospital
becauseofcolinearitywiththevariableofdaysbetween
onsetofillnessandinitialoseltamivirtreatment.Tobet-
ter understandthe causal effectofantimicrobial (oselta-
mivir and antibiotics) intervention and subsequent
development of radiographic pneumonia, we consid-
ered only oseltamivir and antibiotics given before the
presence of radiographic pneumonia.
We used general linear models to identify risk fac-
torsassociatedwithprolongeddurationoffeverandof
viral RNA shedding by using log transformed data.
Candidate variables considered for analysis of pro-
longed duration of fever were sex, age, comorbidities,
smoking, influenza vaccination, presence of radio-
graphic pneumonia, and treatment with oseltamivir.
We also included presence of high fever, cough, spu-
tum,vomiting,anddiarrhoeaforanalysisofprolonged
duration of viral RNA shedding, and, as duration of
fever and viral RNA shedding were positively corre-
lated (Spearman’s ρ 0.417; P<0.001), we included
duration of fever in the multivariable model. For vari-
ables regarding clinical findings, we included symp-
toms developed and treatments given during the
whole clinical course in the analysis.
Table 2 |Clinical symptoms and signs in 1291 patients with 2009 H1N1 virus infection at
hospital admission in China, May-July 2009. Figures are numbers (percentages) unless
stated otherwise
Characteristic
All patients
(n=1291)
Children <15 years
(n=406)
Adults ≥15 years
(n=885)
Clinical symptoms:
Fever 820 (64) 268 (66) 552 (62)
Cough 864 (67) 291 (72) 573 (65)
Sore throat 425 (33) 116 (29) 309 (35)
Sputum 239 (19) 81 (20) 158 (18)
Rhinorrhoea 228 (18) 75 (18) 153 (17)
Headache 211 (16) 57 (14) 154 (17)
Weakness 190 (15) 47 (12) 143 (16)
Nasal congestion 149 (12) 37 (9) 112 (13)
Myalgia 111 (9) 20 (5) 91 (10)
Chill 72 (6) 17 (4) 55 (6)
Nausea 22 (2) 10 (2) 12 (1)
Vomiting 23 (2) 13 (3) 10 (1)
Diarrhoea 19 (1) 5 (1) 14 (2)
Dyspnoea or shortness of breath 0 (0) 0 (0) 0 (0)
Signs:
Pharyngeal congestion 1026 (79) 325 (80) 701 (79)
Swollen tonsils 442 (34) 179 (44) 263 (30)
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Fig 2 | Body temperature over clinical course in 1219 febrile
patients with 2009 influenza H1N1 virus infection
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SPSS, Chicago, IL, USA). For all analyses, probabil-
itiesweretwotailedanda Pvalueof<0.05wasconsid-
ered significant.
RESULTS
Demographic characteristics and comorbidities
From11Mayto31July2009atotalof2126confirmed
cases of 2009 H1N1 were reported.We included 1291
(61%) with available data for chart review reported
from94prefecturesin25provinces(seeappendix1on
bmj.com), which represented 90% (1291/1438) of
patients discharged before 31 July. See bmj.com for
details of patients’ enrolment (appendix 2) and a com-
parison of the characteristics of patients with and with-
out medical records for review (appendix 3). Of the
1291 patients, 406 (31%) were aged <15 years and
were classed as children.
The median age of the patients was 20 years (inter-
quartile range 12-26) and 54% were male (table 1);
most (71%) were aged ≤24. Of the 1291 patients, 64
(5%) had a comorbidity associated with severe influ-
enza; the most common were asthma (2%), other
chronic pulmonary disease (0.8%), and chronic liver
disease (0.8%). Two patients were pregnant, both in
the second trimester.
Clinical symptoms and laboratory findings
Themostcommonsymptomsonadmissionwerefever
(820, 64%), cough (864, 67%), sore throat (425, 33%),
sputum (239, 19%), and rhinorrhoea (228, 18%)
(table 2). Only 4% of the patients reported gastro-
intestinal tract symptoms including diarrhoea, nausea,
orvomiting.Themostcommonsignswerepharyngeal
congestion(1026,79%)andswollentonsils(442,34%).
None of 1291 patients developed symptoms of lower
respiratorytract disease such as dyspnoeaor shortness
of breath. More children than adults experienced
cough, vomiting, and swollen tonsils (table 2).
Table 3 gives details of abnormal haematological
findings at admission, which included leucopenia
(451, 36%), neutropenia (483, 39%), lymphopenia
(252, 21%), thrombocytopenia (34, 3%), and anaemia
(109, 9%) in children and adults. Some patients had
mildly raised biochemical markers including alanine
aminotransferase (110, 10%), aspartate aminotransfer-
ase (127, 12%), creatine kinase (100, 19%), creatine
phosphokinase isoenzymes (51, 11%), lactic dehydro-
genase (119, 17%), and C reactive protein (271, 38%).
Comparedwithadults,childrenmoreoftenhadleuco-
penia, anaemia, or raised aspartate aminotransferase,
creatine phosphokinase isoenzymes, and lactic dehy-
drogenase levels (table 3).
Of the 920 patients who underwent chest radio-
graphy during their stay in hospital, 110 (12%) had
abnormal findings consistent with pneumonia. Radio-
graphy was carried out at a median of two days (inter-
quartilerange,1-3)afteronsetofsymptomsin28(10%)
children and 82 (13%) adults (table 3). Findings
included infiltration in 105 patients and consolidation
in five. The most common features of these
Table 3 |Laboratory findings of 1291 patients with 2009 H1N1 virus infection at hospital
admission in China, May-July 2009. Figures are numbers (percentages) unless stated
otherwise
Characteristic
All patients
(n=1291)
Children <15 years
(n=406)
Adults ≥15 years
(n=885)
Haematology:
Leucopenia 451/1237 (36) 169/388 (44) 282/849 (33)
Neutropenia 483/1233 (39) 182/388 (47) 301/845 (36)
Lymphopenia 252/1229 (21) 84/387 (22) 168/842 (20)
Thrombocytopenia 34/1208 (3) 9/382 (2) 25/826 (3)
Anaemia 109/1211 (9) 74/381 (19) 35/830 (4)
Raised erythrocyte sedimentation
rate
67/228 (29) 33/86 (38) 34/142 (24)
Serum biochemistry:
Alanine aminotransferase >40 U/l 110/1068 (10) 17/332 (5) 93/736 (13)
Aspartate aminotransferase >40 U/l 127/1035 (12) 62/327 (19) 65/708 (9)
Creatinine >177 µmol/l 0/1107 (0) 0/353 (0) 0/754 (0)
Raised creatine kinase 100/524 (19) 39/174 (22) 61/350 (17)
Creatine phosphokinase
isoenzymes >25 U/l
51/460 (11) 31/162 (19) 20/298 (7)
Lactic dehydrogenase >245 U/l 119/717 (17) 77/205 (38) 42/512 (8)
C reactive protein >8 mg/l 271/705 (38) 41/246 (17) 230/459 (50)
Immunological marker:
CD4 <0.35×10
9/l 130/527 (25) 28/132 (21) 102/395 (26)
CD8 <0.24×10
9/l 121/526 (23) 21/131 (16) 100/395 (25)
CD4:CD8 ratio <1.4 279/528 (53) 70/131 (53) 209/397 (53)
Invasive bacterial co-infection 0/36 (0) 0/19 (0) 0/17 (0)
Radiographic diagnosis of pneumonia during admission:
Total 110/920 (12) 28/287 (10) 82/633 (13)
Only infiltrate 105 (95) 27 (96) 78 (95)
Unilateral infiltrate 67 (64) 15 (56) 52 (67)
Bilateral infiltrate 38 (36) 12 (44) 26 (33)
Consolidation:
Total 5 (5) 1 (4) 4 (5)
Unilateral consolidation 4 (80) 1 (100) 3 (75)
Bilateral consolidation 1 (20) 0 (0) 1 (25)
Median (IQR) time (days) from illness
onset to radiographic diagnosis of
pneumonia
2( 1 - 3 ) 2( 1 - 4 ) 2( 1 - 3 )
IQR=interquartile range.
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Fig 3 | Cumulative disappearance of fever and proportion of
patients with undetectable viral RNA by days after onset of
symptoms
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lar infiltration. None of 36 patients who were tested
had bacterial growth from blood cultures.
Treatment and clinical course
The 1291 patients were admitted to hospital a median
of two days (interquartile range 1-3) after onset of
symptoms (table 4). During admission, 983 (76%)
patients were treated with oseltamivir from a median
of day three of symptom onset (2-4) and 363 (37%)
patients within two days of symptom onset. Some 735
(75%) patients received a standard course of oseltami-
vir(fivedays),and110(11%)receivedprolongedtreat-
ment for persistently positive viral RNA. During
hospital admission, 479 (37%) patients received
empirical antibiotics, most commonly cephalosporins
(51%) and macrolides or azithromycin (46%). Few
patientsreceivedcorticosteroids(three)orsupplemen-
taryoxygenviaeithermask(five)ornasalcatheter(13).
None of 1291 patients required admission to an inten-
sive care unit or invasive mechanical ventilation.
Seventy two (6%) patients had no fever throughout
the clinical course. Of the remaining 1219 (94%)
patients who developed fever, most (76%) had fever
on the same day as onset of symptoms, and fever
most commonly disappeared two (24%) or three days
(25%) after onset (fig 1and fig 2). Fever persisted for a
median of two days (interquartile range 1-3). Overall,
the median body temperature of febrile patients had
returned to normal (<37.3°C) three days after onset
(fig 1), and 90% of fevers had disappeared within five
days(fig3).All1291patients’symptomsresolvedfully
at a median of five days (4-7) after onset, and patients
were discharged at a median of eight days (6-10) after
Table 4 |Treatments and clinical course of 1291 patients with 2009 H1N1 virus infection in China, May-July 2009. Figures
are numbers (percentages) unless stated otherwise
Characteristic
All patients
(n=1291)
Children <15 years
(n=406)
Adults ≥15 years
(n=885)
Oseltamivir treatment 983 (76) 299 (74) 684 (77)
Oseltamivir initiation time (days after onset of symptoms):
Median (IQR) 3 (2-4) 3 (2-4) 3 (2-4)
Day 1-2 363 (37) 106 (35) 257 (38)
Day 3-4 476 (48) 153 (51) 323 (47)
Day 5-17 144 (15) 40 (13) 104 (15)
Duration of oseltamivir treatment (days):
Median (IQR) 5 (5-6) 5 (5-6) 6 (5-6)
1-4 138 (14) 39 (13) 99 (14)
5 735 (75) 237 (79) 498 (73)
6-15 110 (11) 23 (8) 87 (13)
Received antibiotics* 479 (37) 129 (32) 350 (40)
Received antipyretics† 340 (26) 143 (35) 197 (22)
Supplementary oxygen treatment‡ 18 (1) 3 (0.7) 15 (2)
Corticosteroid treatment 3 (0.2) 1 (0.2) 2 (0.2)
Median (IQR) time (days) from symptom onset to fever 0 (0-0) 0 (0-0) 0 (0-1)
Median (IQR) time (days) from symptom onset to fever disappearance 3 (2-4) 3 (2-4) 3 (2-4)
Afebrile though clinical course 72 (6) 15 (4) 57 (6)
Median (IQR) time (days) from symptom onset to resolution§ 5 (4-7) 5 (4-7) 5 (4-7)
Median (IQR) time (days) from symptom onset to hospital admission 2 (1-3) 2 (1-3) 2 (1-3)
Median (IQR) time (days) from symptom onset to discharge 8 (6-10) 8 (7-10) 8 (6-9)
IQR=interquartile range.
*Some patients received multiple antibiotics. Major antibiotics include cephalosporins (243, 51%), macrolides or azithromycin (221, 46%),
fluoroquinolones (83, 17%), penicillins (70, 15%), lincomycin (8, 2%), aminoglycosides (4, 1%).
†Some patients received multiple antipyretics. Major antipyretics include paracetamol non-steroidal anti-inflammatory drugs (199, 46%), arylpropionic
acid non-steroidal anti-inflammatory drugs (98, 23%), physical antipyretic measures (51, 12%), salicylic acid non-steroidal anti-inflammatory drugs
(31, 7%).
‡Mask oxygen therapy (n=5); nasal catheter oxygen therapy (n=13).
§Resolution of symptoms defined as disappearance of influenza related symptoms including fever, cough, sore throat, nasal congestion, rhinorrhoea,
myalgia, weakness, etc.
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Fig 4 | Proportion of samples with first positive for viral RNA
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of symptoms
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oseltamivir treatment (β 0.05, 95% confidence interval
0.001 to 0.10) or oseltamivir treatment starting more
than two days after symptom onset (0.15, 0.11 to
0.19) and presence of radiographic pneumonia (0.07,
0.01 to 0.12) were independent factors associated with
a prolonged duration of fever.
Risk factors associated with radiographic pneumonia
In the final multivariable model, which included 920
patients who underwent chest radiography during
their admission to hospital, treatment with oseltamivir
starting within two days (odds ratio 0.17, 95% confi-
dence interval 0.10 to 0.29) or more than two days
(0.09, 0.05 to 0.15) after onset of symptoms were iden-
tified as significant protective factors for radiographic
pneumonia (table 6). When we combined oseltamivir
treatmentstartingwithintwodaysoraftertwodaysfor
multivariableanalyses,therewasnosignificantchange
in the estimate of overall impact on presence of radio-
graphic pneumonia (0.12, 0.08 to 0.18, P<0.001). To
prevent one 2009 H1N1 patient developing radio-
graphic pneumonia, four patients (number needed to
treat 4, 3 to 5) would need to be treated with oseltami-
vir.Withregardtodevelopmentofradiographicpneu-
monia, there seemed to be no more benefit with early
initiation of oseltamivir (within two days of symptom
onset) than with initiation after two days.
Viral RNA shedding
Wehaddataonthefirstpositiveandundetectableviral
RNA results in respiratory specimens for almost all
patients (1289). Those specimens were collected at a
median of one day (0-2) and six days (4-7) after the
onset of symptoms. Specimens with first positive
results were usually collected on the day (29%) of
symptom onset or one day (32%) after, while the sam-
ple with undetectable viral RNA was most commonly
collected at five (16%) or six days (17%) after onset
(fig 4). Specimens positive for viral RNA were col-
lected from 11 patients one day before onset of symp-
toms, while they were under medical observation as
close contacts of cases. Overall, viral RNA was unde-
tectable among most patients (91%) within nine days
aftersymptomonset(fig3). Of the119 (9%)remaining
patients whose first test with undetectable viral RNA
waslaterthanninedaysaftersymptomonset,45(38%)
werechildrenandfive(4%)hadonecomorbidity asso-
ciated with severe influenza, but none of them were
immunosuppressed. The median interval between
the first sample positive for viral RNA and the unde-
tectable RNA was four days (3-6), and the median
interval between disappearance of fever and an unde-
tectable viral RNA level was three days (1-4).
Two previously healthy men had the longest dura-
tion of viral RNA shedding (21 days). One was a
20 year old student with acute respiratory illness; he
also had the longest duration of fever of 16 days. He
receivedoseltamivirtreatmentforfivedays,beginning
two weeks after onset of symptoms. The other was a
28 year old patient with radiographic pneumonia
after five days of fever. He received oseltamivir treat-
ment for 15 days, starting two days after onset.
In the final multivariable model (table 5), no oselta-
mivir treatment (β 0.04, 95% confidence interval, 0.01
to 0.07) or oseltamivir treatment starting more than
two days after symptom onset (0.13, 0.10 to 0.16), pre-
senceofcough(0.07,0.03to0.10),sputum(0.04,0.004
to 0.05), and prolonged durationof fever (0.026, 0.020
to0.032)wereindependentfactorsassociatedwithpro-
longed viral RNA shedding.
DISCUSSION
Principal findings
In people with mild H1N1 infection, treatment with
oseltamivir significantly protects against subsequent
development of radiographically confirmed pneumo-
nia, and early initiation within two days of onset of
symptoms reduces the duration of fever and viral
RNA shedding. We studied 1300 patients with mild
2009H1N1 infection,whomostly presented withclin-
ical features of uncomplicated, self limiting acute
respiratory illness. A minority (12%) of patients had
chest radiography consistent with pneumonia. Three
quarters of patients were treated with oseltamivir dur-
ing admission to hospital. The laboratory analyses
showed that 2009 H1N1 is shed from one day before
onset of symptomsand might beshed for a longerper-
iod of time than seasonal influenza virus.
Table 5 |Multivariable analyses* of risk factors associated with prolonged duration of fever
and duration of viral RNA shedding
Risk factors
No (%) of patients
included in analysis β (95% CI) P value
Duration of fever (n= =951)† †
Oseltamivir:
Started on day 1-2 of symptom onset 246 (26) Reference
Started >2 days after symptom onset 440 (46) 0.15 (0.11 to 0.19) <0.001
No oseltamivir treatment 265 (28) 0.05 (0.001 to 0.10) 0.044
Radiographic pneumonia:
Not present 569/643 (88) Reference
Present 74/643 (12) 0.07 (0.01 to 0.12) 0.018
Prolonged duration of viral RNA (n= =1289)‡ ‡
Oseltamivir:
Started on day 1-2 of symptom onset 363 (28) Reference
Started >2 days after symptom onset 619 (48) 0.13 (0.10 to 0.16) <0.001
No oseltamivir treatment 307 (24) 0.04 (0.01 to 0.07) 0.021
Cough:
Not present 188 (15) Reference
Present 1101 (85) 0.07 (0.03 to 0.10) <0.001
Sputum:
Not present 715 (55) Reference
Present 574 (45) 0.04 (0.004 to 0.05) 0.025
Duration (days) of fever after onset of
symptoms†§
949 (74) 0.03 (0.02 to 0.03) <0.001
*General linear model. β >0 indicates variable increases duration of fever or duration of viral RNA shedding and
β <0 indicates the variable reduces duration of fever or duration of viral RNA shedding. For example, compared
with patients with oseltamivir started on day 1-2 of symptoms, duration of fever would be 1.4 (equal to 10β)
times that in patients with oseltamivir started on >2 days after symptom onset.
†Excluded 340 patients treated with antipyretics.
‡Excludes two patients because data unavailable on time from onset of illness to first sample negative for 2009
influenza H1N1 virus RNA.
§Considered as continuous variable when included in model.
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Atthebeginningofthepandemic,Chinaimplemented
an aggressive containment strategy based on the
national pandemic preparedness plan. Rigorous clini-
cal management, which included isolation of all
patientswithconfirmedinfectionandearlyoseltamivir
treatment, and set discharge criteria, including an
undetectable viral RNA level, provided us with a
uniqueopportunitytostudytheclinicalfeatures,effec-
tiveness of oseltamivir treatment, and the viral RNA
shedding pattern of patients with mild 2009 H1N1.
Our study population was three times the size of one
inarecentstudy
11andprovideduswithamorepower-
fulanalysistodeterminetheeffectofoseltamivironthe
preventionof radiographicallyconfirmed pneumonia.
Most of our patients presented with features of
uncomplicated, self limiting acute respiratory illness,
similar to seasonal influenza.
23 Fever was an early
symptom but was not always present at admission
(36%), and 6% of our patients did not have fever
throughout their clinical course. A meta-analysis
reported that fever occurred in only one third of
healthy participants in experimental seasonal influ-
enza virus infection.
24 Consistent with the duration of
fever in seasonal influenza (three to four days), fever
resolved within five days for most patients. Gastro-
intestinal symptoms were rare (4%), although consis-
tent with adults infected with seasonal influenza,
23 but
much lower than in recent reports of severely affected
patients admitted to hospital with 2009 H1N1
infection.
34 Seasonal influenza is associated with var-
ious signs and symptoms that can vary by age, under-
lying chronic disease, pregnancy, complications, and
host immune status. Clinical features among children
andadultsinourstudyweresimilar,consistentwithan
absenceofimmunitytothisnovelvirus,althougholder
people aged >60 might have pre-existing immunity.
25
Aswithuncomplicatedseasonalinfluenza,inwhichill-
ness typically resolves after three to seven days,
26 our
patients’ symptoms resolved fully within five days of
illness.
Although upper respiratory illness with systemic
symptomsconstitutedthemostcommonpresentation,
a minority (12%) of patients had findings on chest
radiography consistent with pneumonia, but notably
none of them presented with clinical symptoms or
signs of lower respiratory tract disease. Of the patients
with radiographic evidence of pneumonia,most (92%)
received antiviral drugs and 59% received empirical
antibiotics. It is difficult to precisely determine the
cause of pneumonia from radiography, though most
radiographic features of local patchy shadowing and
the negative results of blood cultures in our study
would not seem to support the use of antibiotics for
these mildly affected patients. A current summary of
bacterialisolatesfrom53childrenwhodiedfrom2009
H1N1
27 highlights a challenge facing clinicians who
make decisions about antibiotic treatment in influenza
patients with lower respiratory tract disease. Most
uncomplicated self limiting acute respiratory illness
caused by 2009 H1N1, however, does not require
treatment with antibiotics.
Ourstudysuggeststhat2009H1N1isshedfromone
day before the onset of symptoms to eight days after
onset for most (91%) patients and can be shed up to
21 days. Consistent with two small observational stu-
diesinSingapore
28andCanada,
29ourresultsshowthat
2009 H1N1 can be shed for a longer period of time
than seasonal influenza virus. The latter is usually
shed for five days after onset of symptoms in
adults,
3031 although the virus can be isolated up to
two weeks after the onset of symptoms in children
and even longer in immunocompromised
individuals.
3233 One study isolated viable pandemic
H1N1 virus in 24% of samples taken seven days after
theonsetofillnessinadults.
34Influenzavirusshedding
usually stops once the illness has resolved.
33 In our
study, however, though viral RNA shedding corre-
lated with the duration of fever, viral RNA negativity
lagged behind the resolution of fever by a median of
three days. Although the viral RNA shedding by real
time reverse transcription polymerase chain reaction
might not reflect the true infectious period, our results
suggest current infection control guidance
2035 on the
duration of isolation precautions for patients admitted
to hospital (24 hours after the resolution of fever and
respiratorysymptoms) might be too short and patients
might be infectious for longer.
Three quarters of our patients received oseltamivir
treatment, and 37% of them were given treatment
within two days of symptom onset. Thus, we analysed
theeffectivenessofoseltamivirtreatmentonthesubse-
quent development of radiographic evidence of pneu-
moniaandontwoquantitativeindicators—durationof
fever and viral RNA shedding—rather than grouping
only duration of viral RNA shedding as in a recent
study.
11 Our study suggests that oseltamivir reduces
the risk of radiographically confirmed pneumonia,
and early treatment within two days of symptoms
onset can reduce the duration of fever and viral RNA
shedding. Two small observational studies on 2009
H1N1 also suggested that early oseltamivir treatment
Table 6 |Multivariable analyses* of risk factors associated with presence of radiographic diagnosis of pneumonia
No diagnosis of
pneumonia (n=810)
Diagnosisofpneumonia
(n=110)
Odds ratio
(95% CI) P value
No oseltamivir treatment 163 (20) 75 (68) Reference
Oseltamivir started >2 days after symptom onset 406 (50) 16 (15) 0.09 (0.05 to 0.15) <0.001
Oseltamivir started on day 1-2 of symptom onset 241 (30) 19 (17) 0.17 (0.10 to 0.29) <0.001
*Multivariable logistic regression model. OR >1 indicates variable is risk factor and OR <1 indicates variable is protective factor.
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28 viral load, and
durationoffever.
36Theevidencefrompreviousrando-
mised controlled trials of uncomplicated seasonal
influenza is strongest for antiviral treatment started
within 48 hours of illness onset.
13-17 Current guidance
recommends that antiviral treatment should be
initiated immediately and without waiting for labora-
tory confirmation of diagnosis.
2037 Observational stu-
dies suggest that neuraminidase inhibitor treatment of
patients in hospital can reduce disease severity and
mortality, both for 2009 H1N1
3610 and seasonal
influenza.
38-40 Our results, however, do not suggest
that early initiation of oseltamivir (that is, less than
two days after onset) was more protective than later
initiation. Consistent with the observational studies
on seasonal infection
4041 and human infection with
H5N1,
42 our patients still seemed to gain benefit (pre-
vention of radiographically confirmed pneumonia)
even when they received antiviral treatment more
than48hoursaftersymptomonset.Antiviraltreatment
should ideally be started early after the onset of symp-
toms, but it can also be used at any stage of active dis-
ease if ongoing viral replication is anticipated or
documented.
2043
We believe the absence of severely affected patients
in our series is because of early admission to hospital
and early treatment with oseltamivir for most patients.
In contrast to previous reports on severely affected
patients admitted to hospital in countries with sus-
tainedcommunity-widetransmission,
2-9ourcaseseries
reflects only the most commonly affected—that is,
young healthy adults—at the beginning of the pan-
demic, which is not representative of the general Chi-
nese population. Also, the prevalence of risk factors
associated with severe disease from 2009 H1N1,
including chronic comorbidities, pregnancy, and very
youngage,inourpatientsismuchlowerthaninrecent
reports of severely affected patients admitted to
hospital.
2-10 These differences are probably because
we included all patients positive for reverse transcrip-
tion polymerase chain reaction, whereas in the other
studies requirement for admission to hospital was an
additional criterion.
Limitations of study
Our study was limited to data available for early 2009
H1N1 cases identified through surveillance during the
study period, did not include all confirmed patients,
and was inevitably retrospective. For timeliness to
inform public health policy, we included only 90% of
patientsdischargedduringthestudyperiodthatended
on 31 July, and we have no information on patients
who were still in hospital when the study ended. Not
all patients underwent radiography, which could have
introduced selection bias. Participation in the study
was voluntary and was therefore subject to reporting
bias. The national surveillance system might not have
identified all cases of 2009 H1N1, especially among
severely affected people. All laboratory testing was
clinically driven, and tests were not carried in a stan-
dardised fashion. We did not attempt viral isolation to
show the actual viral shedding pattern and conducted
antiviralresistanceanalysisforpatientswithprolonged
antiviral treatment and viral RNA shedding. We also
did not collect data on adverse events attributable to
oseltamivirandonwhy24%ofpatientsdidnotreceive
oseltamivir. Inevitably, there was circularity of report-
ing on clinical features of the illness in patients who
were selected according to the case definition that
included these features.
Conclusion
In conclusion,during the early phase ofthe pandemic,
Chinese patients with 2009 H1N1 infection predomi-
nantly presented with features of uncomplicated, self
limiting acute respiratory illness. 2009 H1N1 is shed
for longer than seasonal influenza virus. Oseltamivir
treatment was identified as a significant protective fac-
tor against subsequent development of radiographic
pneumonia, faster fever clearance times, and shorter
viral RNA shedding. These findings are consistent
with patients with the new 2009 H1N1 benefiting
fromuseofoseltamivir.Giventheretrospectivedesign
ofthisworkandthefactthatnotallpatientsunderwent
radiography, however, our finding that oseltamivir
treatment protected against subsequent radiographic
pneumonia should be interpreted with caution. Con-
tinued investigation is needed to define the effective-
ness of antiviral treatment, pharmacokinetic and
pharmacodynamic parameters, viral shedding pat-
terns, and risk factors for an increased severity of ill-
ness, which will allow for improvement both in
clinical treatment and public health guidance.
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